About Kamada (NASDAQ:KMDA)
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472
Debt
Debt-to-Equity Ratio0.02%
Current Ratio3.30%
Quick Ratio2.58%
Price-To-Earnings
Trailing P/E Ratio25.83
Forward P/E Ratio21.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$102.82 million
Price / Sales1.80
Cash Flow$0.2556 per share
Price / Cash18.00
Book Value$2.22 per share
Price / Book2.07
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$6.90 million
Net Margins6.71%
Return on Equity9.06%
Return on Assets6.46%
Miscellaneous
Employees377
Outstanding Shares40,260,000
Kamada (NASDAQ:KMDA) Frequently Asked Questions
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.10. The biotechnology company had revenue of $35.71 million for the quarter, compared to the consensus estimate of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. View Kamada's Earnings History.
When is Kamada's next earnings date?
What price target have analysts set for KMDA?
3 Wall Street analysts have issued 12-month target prices for Kamada's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Kamada's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Kamada.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Clearside Biomedical (CLSD), Dermira (DERM), Kadmon (KDMN), Merus (MRUS), Seres Therapeutics (MCRB), AVEO Pharmaceuticals (AVEO), Zymeworks (ZYME), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), BioSpecifics Technologies (BSTC), Celyad (CYAD), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Syndax Pharmaceuticals (SNDX), Minerva Neurosciences (NERV) and ArQule (ARQL).
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Leon Yehuda Recanati, Chairman of the Board (Age 67)
- Amir London, Chief Executive Officer (Age 46)
- David Tsur, Deputy Chairman of the Board (Age 67)
- Chaime Orlev, Chief Financial Officer (Age 46)
- Ruth Wolfson, Senior Vice President - Scientific Affairs (Age 69)
- Barak Bashari, Vice President - Operations (Age 51)
- Shani Dotan, Vice President - Human Resources (Age 42)
- Yael Brenner, Vice President - Quality (Age 52)
- Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D (Age 50)
- Eran Schenker, Vice President - Medical Director (Age 53)
Has Kamada been receiving favorable news coverage?
News headlines about KMDA stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kamada earned a daily sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.82 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Kamada?
Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kamada's stock price today?
One share of KMDA stock can currently be purchased for approximately $4.60.
How big of a company is Kamada?
Kamada has a market capitalization of $187.22 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 377 workers across the globe.
How can I contact Kamada?
Kamada's mailing address is 7 SAPIR STREET KIRYAT WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7414002. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]
MarketBeat Community Rating for Kamada (KMDA)
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kamada (NASDAQ:KMDA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Kamada in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 52.17%. The high price target for KMDA is $7.00 and the low price target for KMDA is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $8.50 | $8.50 |
| Price Target Upside: | 52.17% upside | 35.92% upside | 75.26% upside | 75.26% upside |
Kamada (NASDAQ:KMDA) Consensus Price Target History
Kamada (NASDAQ:KMDA) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Kamada (NASDAQ:KMDA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kamada (NASDAQ KMDA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 9.14%
Kamada (NASDAQ KMDA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Kamada (NASDAQ KMDA) News Headlines
| Source: |
|
Kamada (NASDAQ:KMDA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement
Kamada (NASDAQ KMDA) Stock Chart for Thursday, April, 19, 2018
Loading chart…
